Lantheus marked a -5.9% change today, compared to 2.0% for the S&P 500. Is it a good value at today's price of $62.16? Only an in-depth analysis can answer that question, but here are some facts that can give you an idea:
-
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.
-
Lantheus belongs to the Health Care sector, which has an average price to earnings (P/E) ratio of None and an average price to book (P/B) of None
-
The company's P/B ratio is 7.69
-
Lantheus has a trailing 12 month Price to Earnings (P/E) ratio of 126.9 based on its trailing 12 month price to earnings (EPS) of $0.49 per share
-
Its forward P/E ratio is 10.2, based on its forward earnings per share (EPS) of $6.09
-
LNTH has a Price to Earnings Growth (PEG) ratio of 0.32, which shows the company is very undervalued compared to its earnings growth estimates.
-
Over the last four years, Lantheus has averaged free cash flows of $26.88 Million, which on average grew -18.3%
-
LNTH's gross profit margins have averaged 41.7 % over the last four years and during this time they had a growth rate of None % and a coefficient of variability of None %.
-
Lantheus has moved 4.0% over the last year compared to 17.0% for the S&P 500 -- a difference of -13.0%
-
LNTH has an average analyst rating of buy and is -47.49% away from its mean target price of $118.38 per share